RELIEF THERAPEUTICS Holding (MMTX) AI Stock Analysis

• Market Cap: CHF64.22M
• Dividend Yield: N/A
• Average Volume (3M): 252.50K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.44
• Revenue Growth: -52.81%
• EPS Growth: 63.16%
• Country: CH
• Employees: 31
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 159,102,450
• 10 Day Avg. Volume: 727,811
• 30 Day Avg. Volume: 252,501
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.08
• Revenue Forecast (FY): CHF5.50M

• Rating: 41 Neutral
• Price Target: CHF1.00
• Action: Reiterated Date: 01/24/26
• Date: Action: Reiterated 01/24/26

The score is primarily held back by weak financial fundamentals (continued losses and negative free cash flow) and bearish technicals (below major moving averages with negative MACD). Valuation does not provide support because the company is unprofitable and no dividend yield is available.

Positive Factors

High gross margin

A gross margin of ~69% provides a durable structural cushion versus peers, implying product or cost advantages on core offerings. Sustained high gross margins give management flexibility to invest in R&D and commercialization while dampening the revenue growth needed to approach operating profitability over time.

Very low financial leverage

Extremely low leverage and a strong equity ratio reduce solvency risk and preserve strategic optionality through clinical cycles. This structural balance-sheet strength supports access to capital, strategic partnerships, and cushioning against development setbacks without urgent refinancing pressure.

Diversified revenue/funding model

A business model that includes licensing, milestone payments, royalties, and grants distributes commercial risk and provides non-dilutive funding pathways. Structurally, this reduces dependency on product sales timing and enables capital-efficient advancement of the pipeline through partnerships and staged payments.

Negative Factors

Persistent negative profitability

Ongoing net losses and negative operating margins indicate the core business is not yet self-sustaining. Over the medium term the company must either achieve sustained positive operating leverage or secure repeated external funding, otherwise cash burn will constrain R&D and commercialization plans.

Negative free cash flow

Negative free cash flow limits the firm's ability to internally fund trials and commercialization costs, forcing reliance on equity or partnership financing. While improvement is positive, durable operational health requires consistent positive FCF to reduce dilution risk and finance long-term growth.

Unprofitable with no dividend support

Being unprofitable removes earnings-derived resilience and eliminates dividend income as investor support. Structurally this heightens dependence on capital markets and strategic deals for runway, increasing dilution and execution risk if clinical or commercialization milestones slip.

RELIEF THERAPEUTICS Holding Business Overview & Revenue Model

Company Description

MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company was incorporated in 2025 and is based in Lausanne, Switzerland.

How the Company Makes Money

RELIEF THERAPEUTICS generates revenue through multiple channels, including the development and licensing of its drug candidates to pharmaceutical companies, which may involve milestone payments and royalties on sales. The company may also engage in strategic partnerships and collaborations with other biotech firms to co-develop therapies, sharing both costs and profits. Additionally, RLF may receive funding through grants and public offerings, particularly for its research initiatives aimed at advancing its product pipeline. These revenue streams are supplemented by potential future sales of approved therapies in the market.

RELIEF THERAPEUTICS Holding Financial Statement Overview

Summary

Revenue growth and improved gross margin are positives, and leverage is low with a strong equity ratio. However, ongoing net losses, negative EBIT/EBITDA margins, and negative free cash flow keep overall financial strength weak.

Income Statement

The company shows some improvement in revenue, with a 39.5% growth from the previous year. Gross profit margin improved to 69.4%, but net profit remains negative, impacting the overall profitability. EBIT and EBITDA margins are negative, indicating operational challenges and inefficiencies.

Balance Sheet

The debt-to-equity ratio is low at 0.06, suggesting limited leverage. However, the return on equity is negative due to continued net losses. The equity ratio is strong at 68.9%, indicating financial stability with a substantial equity base.

Cash Flow

Free cash flow remains negative, but it has improved compared to the previous year. The operating cash flow to net income ratio is less relevant due to negative net income. The company needs to improve cash generation to support operations and growth.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

RELIEF THERAPEUTICS Holding Technical Analysis

• Last Price: ―

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MMTX, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for CH:MMTX.

RELIEF THERAPEUTICS Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

RELIEF THERAPEUTICS Holding Corporate Events

MindMaze Sets Global Reimbursement Framework to Scale AI-Powered Neurorehabilitation

MindMaze Therapeutics has detailed a coordinated global reimbursement strategy designed to scale access to its next-generation digital neurorehabilitation therapies and underpin long-term commercial growth. Central to the plan is a U.S. CMS Category III code that reimburses high-intensity, home-based, clinician-supervised digital neurorehabilitation as a service rather than as hardware, marking one of the first reimbursement pathways to recognize AI-driven, remotely supervised neurotherapeutic care at scale. This U.S. framework is complemented by participation in Switzerland’s CHF 11.2 million Innosuisse-backed SwissNeuroRehab flagship consortium to generate national-level clinical and health-economic evidence, and by alignment with NICE digital health evaluation standards in the UK to support future NHS adoption. With more than 27 completed clinical studies, 11 regulatory clearances and a data engine processing over 1.2 billion data points per month, the company positions this integrated reimbursement and evidence-generation approach as a foundation for durable reimbursement, expanded patient access and strengthened competitive standing in AI-powered neurorehabilitation across major healthcare markets.

The most recent analyst rating on (CH:MMTX) stock is a Sell with a CHF2.00 price target. To see the full list of analyst forecasts on RELIEF THERAPEUTICS Holding stock, see the CH:MMTX Stock Forecast page.